Palliative Care

  • Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

2025-11-06T09:48:38+02:00November 6, 2025|Investor Information, Psychedelic News|

Psyence BioMed will host an exclusive investor and shareholder webinar on September 16, 2025, at 12:00 PM EST, featuring members of its Scientific Advisory Board. The session will highlight the Company’s ongoing clinical development programs and share insights into future strategic initiatives, with expert contributions from Dan Stein, Seth Feuerstein, Albert Garcia-Romeu, and Clive Ward-Able.

Read More

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

2024-09-16T13:55:07+02:00September 14, 2024|Investor Information, Press Releases, Psychedelic News|

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of naturally derived psilocybin-based therapeutics, today announced that the first site initiation visit has been successfully completed at the first Australian clinical trial site for the Company’s Phase IIb study of nature derived (non-synthetic) psilocybin as a potential treatment for Adjustment Disorder in the Palliative Care context.

Read More

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

2024-09-12T08:28:18+02:00September 11, 2024|Investor Information, Press Releases, Psychedelic News|

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of naturally derived psilocybin-based therapeutics, today announced that the first site initiation visit has been successfully completed at the first Australian clinical trial site for the Company’s Phase IIb study of nature derived (non-synthetic) psilocybin as a potential treatment for Adjustment Disorder in the Palliative Care context.

Read More

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

2024-08-27T09:58:34+02:00April 18, 2024|Investor Information, Press Releases, Psychedelic News|

Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context has been listed on the Australian New Zealand Clinical Trials Registry (“ANZCTR”), under registration number 12624000449538p. The randomized, double-blind, placebo-controlled Phase IIb study will test three doses (25mg, 10mg and 1mg) of nature-derived psilocybin in 84 patients in conjunction with psychotherapy. Psyence Biomed anticipates enrolling the first subject in the second quarter of 2024 and expects the primary endpoint results to be available in 2025.

Read More

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

2024-08-27T10:00:45+02:00April 9, 2024|Investor Information, Press Releases|

has entered into a partnership with Fluence, a global leader in professional education and training for psychedelic therapy research, and iNGENū CRO Pty Ltd (“iNGENū”), an Australian clinical research organization (CRO), to support an upcoming Phase llb clinical trial. The trial will explore the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for the treatment of Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.

Read More
Go to Top